ArticleInternational journal of molecular sciences2020
Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Polymorphisms inFrontiers in pharmacology · 2025Pooled it
- Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.Clinical and translational science · 2022Pooled it
- Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.Clinical and translational science · 2021Trial
- Impact of lymphocyte p-glycoprotein activity on development of graft-versus-host disease after stem cell transplantation.International journal of hematology · 2026Article
- Further Personalizing Medicine in Immune Disorders: Genomic Findings and Hematopoietic Cell Transplantation Survival.Transplantation · 2026Article
- A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing.Clinical pharmacokinetics · 2025Article
- A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients.Pharmaceutics · 2023Article
- Article
- Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID-19 pandemic.Clinical and translational science · 2022Article
- Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients.Pharmacogenomics · 2022Article
- Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients.Frontiers in pharmacology · 2022Article
- [The effect of CYP3A5 gene polymorphism on tacrolimus concentration and adverse events in patients undergoing allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation.Frontiers in pharmacology · 2021Article
- Implementation and Initial Evaluation of a Research and Scholarship Training Pathway in a Doctor of Pharmacy Curriculum.American journal of pharmaceutical education · 2021Article
- Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients.Journal of clinical medicine · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 2 institutions in 1 country.
Jing ZhuThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Tejendra PatelThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Jordan A MillerDepartment of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC 27599, USA.
Chad D TorriceThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Mehak AggarwalThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Margaret R SketchThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3879-0346
Maurice D AlexanderDepartment of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3092-6050
Paul M ArmisteadDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
James M CoghillDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Tatjana GrgicDepartment of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC 27599, USA.
Katarzyna J JamiesonDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Jonathan R PtachcinskiDepartment of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC 27599, USA.ORCID 0000-0002-9987-6613
Marcie L RichesDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0003-0257-0990
Jonathan S SerodyDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
John L SchmitzDepartment of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.
J Ryan ShawDepartment of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC 27599, USA.
Thomas C SheaDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Oscar SuzukiThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Benjamin G VincentDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
William A WoodDivision of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Kamakshi V RaoDepartment of Pharmacy, University of North Carolina Hospitals and Clinics, Chapel Hill, NC 27599, USA.
Tim WiltshireThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.
Eric T WeimerDepartment of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3677-5724
Daniel J CronaThe Center for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3742-8863
University of North Carolina at Chapel Hill · USUniversity of North Carolina Hospitals · US
Funding
Research Training in Hematology at UNC Chapel HillT32HL007149 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nigel S. Key · 1985 to 2026
$8.6MMechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHDR01HL139730 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SERODY, JONATHAN S. · 2017 to 2020
$2.2MNHLBI NIH HHS 5T32HL007148-43NHLBI NIH HHS R01 HL139730NHLBI NIH HHS T32 HL007149
Abstract
Tacrolimus exhibits high inter-patient pharmacokinetics (PK) variability, as well as a narrow therapeutic index, and therefore requires therapeutic drug monitoring. Germline mutations in cytochrome P450 isoforms 4 and 5 genes (
Indexed as
Hematopoietic Stem Cell TransplantationAdultAgedATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP3ADatabases, GeneticFemaleGenotypeGerm-Line MutationGraft vs Host DiseaseHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedOdds RatioATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimusABCB1allogeneic hematopoietic stem cell transplantCYP3A4/5germlinepharmacodynamicspharmacogeneticspharmacokineticssingle nucleotide polymorphism (SNP)tacrolimus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.